Company Overview of Hepregen Corporation
Hepregen Corporation develops bio-engineered solutions for drug discovery and development applications in the pharmaceutical industry. The company develops and commercializes HepatoPac, a bio-engineered micro-liver platform for use in a range of applications, including metabolite identification, toxicity screening, clearance, drug-drug interactions, transporter involvement, in silico models, toxicogenomics, and disease modeling applications in humans; and HepatoMune, a micro-liver assay kit to predict toxicologic outcomes caused by the interaction of drugs and/or biologics with an inflamed liver. Its solutions are also used in cosmetic and environmental testing industries. The company was fo...
200 Boston Avenue
Medford, MA 02155
Founded in 2007
Key Executives for Hepregen Corporation
Chief Executive Officer and Director
Co-Founder, President and Director
Co-Founder and Director of Research
Chief Financial Officer and Vice President of Finance and Administration
Vice President of Operations
Compensation as of Fiscal Year 2015.
Hepregen Corporation Key Developments
SOLVO Biotechnology and Hepregen Corp. Sign Co-Marketing Pact
Jun 26 15
SOLVO Biotechnology and Hepregen Corp. reported the Study of Xenobiotics, a co-marketing agreement between the companies. This agreement provides for the European marketing of Hepregen's human, monkey, rat and dog application-directed HepatoPac and HepatoMune kits, which are used for liver metabolite analysis, transport studies and predictive and mechanistic toxicology studies. These kits contain human or animal hepatocytes (liver cells) in Hepregen's proprietary micro-patterned, co-culture microtiter tissue culture plates. This agreement provides SOLVO with the opportunity to make services available to its customers using these Hepregen products as well as HepatoPac B-CLEAR products co-developed by Hepregen and Qualyst Transporter Solutions.
Hepregen Corporation Launches First Dog HepatoPac Assay Kit to Evaluate Metabolism in the Laboratory
Jan 29 15
Hepregen Corporation announced the commercial launch of the company's first dog HepatoPac kit designed specifically for metabolite identification and profiling applications. Each kit contains one or more standard 24-well tissue culture plates featuring uniquely configured micro-patterned dog liver cells co-cultured with specially selected stromal cells that support the high level of performance observed in Hepregen's micro-patterned co-culture platform. The dog liver cells (hepatocytes) on these plates mirror the behavior of liver cells in live animals, enabling scientists to generate data that can be useful for evaluation of the metabolism of chemical agents, including drug candidates, improving the design of preclinical experiments. The remarkable flexibility of Hepregen's micro-patterned HepatoPac® platform allowed Hepregen scientists to develop a dog product that provides investigators with uniquely stable canine hepatocytes. The tissue culture maintains functionality and morphology for weeks, enabling experiments not previously possible.
Hepregen Corporation Launches Dual-Species HepatoPac™ DMPK Assay Kits for Metabolite Identification and Profiling
Sep 24 14
Hepregen Corporation announced the commercial launch of the company’s first application-oriented, dual-species HepatoPacTM kit designed specifically for use in metabolite identification and profiling. Each kit contains one standard 24-well tissue culture plate, half containing micro-patterned human hepatocytes, and the other half containing micro-patterned rat hepatocytes (available in Wistar-Hahn or Sprague-Dawley strains). The hepatocytes on these plates from both species remain fully functional for up to two months. These unique dual-species kits provide customers with a plug-in-ready product, designed for use in evaluating metabolite production in a discovery or development setting, or in any case where a quick comparative answer is beneficial.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|